Noradrenergic and adrenergic signaling

Noradrenergic and adrenergic signaling constitute the principal catecholaminergic systems mediating the body's "fight-or-flight" response, arousal, attention, and cardiovascular homeostasis. Norepinephrine and epinephrine are synthesized from L-tyrosine via tyrosine hydroxylase (rate-limiting), dopamine β-hydroxylase (converting dopamine to norepinephrine), and phenylethanolamine N-methyltransferase (producing epinephrine in the adrenal medulla) (Nagatsu, 1991; Axelrod, 1971). Norepinephrine functions primarily as a neurotransmitter, while epinephrine acts mainly as a circulating hormone (Goldstein, 2010).

Central noradrenergic neurons originate in the locus coeruleus (LC), providing widespread projections to cortex, hippocampus, and spinal cord, regulating arousal, vigilance, and attention (Aston-Jones & Cohen, 2005). The LC exhibits tonic (baseline arousal) and phasic (salient stimulus) firing modes. Signaling is terminated by NET-mediated reuptake and enzymatic degradation (Eisenhofer et al., 2004). Norepinephrine and epinephrine act through nine GPCR subtypes: α1 (Gαq, vasoconstriction), α2 (Gαi/o, presynaptic inhibition, sedation), and β1-3 (Gαs, cardiac stimulation, bronchodilation, lipolysis) (Philipp & Hein, 2004; Bylund, 1992). α2 autoreceptors provide negative feedback on norepinephrine release.

Functionally, the noradrenergic system enhances arousal, attention, and memory consolidation via an inverted-U dose-response curve (Arnsten, 2011). Peripherally, it mediates sympathetic vasoconstriction, increased heart rate, and metabolic mobilization. Pathologically, LC degeneration contributes to cognitive decline in Alzheimer's and Parkinson's disease (Weinshenker, 2018). Dysregulated noradrenergic tone is implicated in PTSD (hyperarousal), depression (reduced tone), and ADHD, treated with NET inhibitors like atomoxetine (Bymaster et al., 2002). β-blockers (e.g., propranolol) treat hypertension and migraine; α1-antagonists (e.g., prazosin) treat hypertension and BPH; α2-agonists (e.g., clonidine) treat hypertension and ADHD (Ram & Kaplan, 2011). In summary, noradrenergic/adrenergic signaling, through diverse α and β receptors, regulates arousal, attention, autonomic function, and stress, with therapeutic relevance across neurodegenerative, psychiatric, and cardiovascular disorders.

References

Arnsten, A. F. T. (2011). Catecholamine influences on dorsolateral prefrontal cortical networks. Biological Psychiatry, 69(12), e89–e99.

Aston-Jones, G., & Cohen, J. D. (2005). An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annual Review of Neuroscience, 28, 403–450.

Axelrod, J. (1971). Noradrenaline: Fate and control of its biosynthesis. Science, 173(3997), 598–606.

Bylund, D. B. (1992). Subtypes of α1- and α2-adrenergic receptors. FASEB Journal, 6(3), 832–839.

Bymaster, F. P., Katner, J. S., Nelson, D. L., et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat. Neuropsychopharmacology, 27(5), 699–711.

Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004). Catecholamine metabolism: A contemporary view. Pharmacological Reviews, 56(3), 331–349.

Goldstein, D. S. (2010). Adrenal responses to stress. Cellular and Molecular Neurobiology, 30(8), 1433–1440.

Nagatsu, T. (1991). Genes for human catecholamine-synthesizing enzymes. Neuroscience Research, 12(2), 315–345.

Philipp, M., & Hein, L. (2004). Adrenergic receptor knockout mice: Distinct functions of 9 receptor subtypes. Pharmacology & Therapeutics, 101(1), 65–74.

Ram, C. V. S., & Kaplan, N. M. (2011). Alpha-blockers in the treatment of hypertension. Journal of Clinical Hypertension, 13(7), 517–522.

Weinshenker, D. (2018). Long road to ruin: Noradrenergic dysfunction in neurodegenerative disease. Trends in Neurosciences, 41(4), 211–223.